Ever since then, with the application of microsurgical neurovascular devices, the life-expectancy of patients with neurovascular disorders has raised remarkably. During our research, we identified over 50 device developers engaged in the global neurovascular devices market.

The global neurovascular devices market size is projected to grow from $3,325 million in 2024 to $7,011 million by 2035, representing a CAGR of 7.02%, during the forecast period, till 2035.

Majority (49%) of the developers were established during the period post-2010. Moreover, there has been an increase in the number of developers entering the neurovascular devices domain over the past decades, reflecting a stable and enticing industry for the new entrants. Examples of developers established post-2020 include (in reverse chronological order, established post-2017) Artiria Medical (2019), Perfuze (2018), HeMo Bioengineering (2018), Ceretrieve (2018) and Vesalio (2018).

It is worth highlighting that more than 305 neurovascular devices have either received regulatory approval or are currently being commercialized for patients diagnosed with different types of neurovascular disorders. In fact, 10% of the neurovascular devices are currently being evaluated in clinical trials to assess the safety and effectiveness of these devices in neurovascular disorders.

Over 29% of the devices are utilized for the treatment of cerebral aneurysms, followed by devices used to treat ischemic strokes (24%). This can be attributed to fact that cerebral aneurysms and ischemic stroke have the highest global incidence rate. ,   Further, close to 15% of the neurovascular devices are available for the treatment of arteriovenous fistulae. Notable examples of devices used to treat cerebral aneurysms include (in alphabetical order, aneurysm stents / implants) ACCERO heal Stent (Acandis), ACCERO Rex Stent (Acandis), ACCERO Stent (Acandis), ACCLINO heal Stent (Acandis), ACCLINO flex plus Stent (Acandis), pCONUS 1 Bifurcation Aneurysm Implant (Phenox) and pCONUS 2 Bifurcation Aneurysm Implant (Phenox).

Several partnerships have been inked in this domain, since 2019. During our research, we came across several partnerships and collaborations that have been inked between different stakeholders engaged in the global neurovascular devices market. It is worth mentioning that the number of partnerships inked in this domain has increased over time at a CAGR of 52%, since 2019.

Most of the deals (25%) were distribution agreements, wherein companies partner with other companies to distribute their devices across various geographical regions. Notable examples of distribution agreements signed in 2023 include (in reverse chronological order) collaboration between Rapid Medical and Kaneka (December 2023), Embolx and Girlow (November 2023), Skynor Medical and Pearce Medical (October 2023) and Embolx and Cardiva Italia (March 2023).

In addition, a maximum number of collaborations have been inked by players based in North America; of which 30% deals are intracontinental agreements and 70% deals are intercontinental agreements. Further, the majority of the players based in North America signed intercontinental agreements with stakeholders headquartered in Europe (64%), followed by stakeholders headquartered in Asia-Pacific and rest of the world-based (36%). Examples of recent deals signed between players based in North America and Europe include (in reverse chronological order, acquisition) Stryker Corporation and Cerus Endovascular (May 2023), Wallaby Medical and Phenox (April 2022). Further, players headquartered in Europe inked 5 intracontinental and 2 intercontinental deals with various stakeholders engaged in this domain.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/neurovascular-devices-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.             

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact Details

Roots Analysis 

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com 

Website: https://www.rootsanalysis.com/